Israel’s BioLight Life Sciences Investments announced that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other countries.
Non-invasive test for bladder cancer
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.